Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children

Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India

(2014) Matthew Bonaparte et al.   BMC INFECTIOUS DISEASES

Primary Immunization of Infants and Toddlers in Thailand with Japanese Encephalitis Chimeric Virus Vaccine in Comparison with SA14-14-2

(2014) Emmanuel Feroldi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan

(2014) Li-Min Huang et al.   VACCINE

A randomized study of the immunogenicity and safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in comparison with SA14-14-2 Vaccine in children in the Republic of Korea

(2014) Dong Soo Kim et al.   Human Vaccines & Immunotherapeutics

The Incidence of Japanese Encephalitis in Taiwan—A Population-Based Study

(2014) Li-Ching Hsu et al.   PLoS Neglected Tropical Diseases

Estimation of the Impact of a Japanese Encephalitis Immunization Program with Live, Attenuated SA 14-14-2 Vaccine in Nepal

(2013) Shyam Raj Upreti et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children

(2013) Emmanuel Feroldi et al.   Human Vaccines & Immunotherapeutics

Epidemiology of Japanese encephalitis in South Korea, 2007–2010

(2012) Dong-Woo Lee et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine

(2012) Kamal Desai et al.   VACCINE

Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial

(2012) Emmanuel Feroldi et al.   Human Vaccines & Immunotherapeutics

Estimated global incidence of Japanese encephalitis:

(2011) Grant Campbell et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine

(2011) Peter E Nasveld et al.   Human vaccines & immunotherapeutics

Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine

(2011) Peter E. Nasveld et al.   Human vaccines & immunotherapeutics

Emergence of Genotype I of Japanese Encephalitis Virus as the Dominant Genotype in Asia

(2011) X.-L. Pan et al.   JOURNAL OF VIROLOGY

Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: A case–control study

(2011) Charung Muangchana et al.   VACCINE

IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine

(2010) Mohan Babu Appaiahgari et al.   Expert Review of Vaccines

Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-olds

(2010) Kulkanya Chokephaibulkit et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials

(2010) Joseph Torresi et al.   VACCINE

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

(2009) Bruno Guy et al.   VACCINE